Assessment of HER2 testing patterns, HER2+ disease, and the utilization of HER2-directed therapy in early breast cancer

David D Stenehjem1 Pharmacotherapy Outcomes Research Center (PORC), College of Pharmacy, University of Utah, Salt Lake City, UT, USA;2 Huntsman Cancer Institute, Salt Lake City, UT, USACorrespondence[email protected]

Minkyoung Yoo1 Pharmacotherapy Outcomes Research Center (PORC), College of Pharmacy, University of Utah, Salt Lake City, UT, USA

Sudhir K Unni1 Pharmacotherapy Outcomes Research Center (PORC), College of Pharmacy, University of Utah, Salt Lake City, UT, USA

Mukul Singhal1 Pharmacotherapy Outcomes Research Center (PORC), College of Pharmacy, University of Utah, Salt Lake City, UT, USA

Hillevi Bauer1 Pharmacotherapy Outcomes Research Center (PORC), College of Pharmacy, University of Utah, Salt Lake City, UT, USA

Kim Saverno1 Pharmacotherapy Outcomes Research Center (PORC), College of Pharmacy, University of Utah, Salt Lake City, UT, USA

Cheng Quah3 Genentech, Inc., South San Francisco, CA, USA

Anthony Masaquel3 Genentech, Inc., South San Francisco, CA, USA

Diana I Brixner1 Pharmacotherapy Outcomes Research Center (PORC), College of Pharmacy, University of Utah, Salt Lake City, UT, USA;4 Program in Personalized Health Care, University of Utah, Salt Lake City, UT, USA

show all

Figures & data

Figure 1 Patient flow, HER2 status, and HER2-directed therapy utilization.

Abbreviations: ICD-O, International Classification of Diseases for Oncology; n, number; ICD, International Classification of Diseases; EDW, enterprise data warehouse; HER2, human epidermal growth factor receptor 2.

Table 1 Demographic and clinical characteristics of the study population stratified based on stage (N=1,458)

Download CSV Display Table

Figure 2 HER2 positivity by (A) age, (B) estrogen receptor/progesterone receptor, (C) grade, and (D) stage.

Abbreviations: n, number; HER2, human epidermal growth factor receptor 2.

Table 2 Status of HER2 testingTable Footnote* before and after the establishment of ASCO/CAP guidelines

Download CSV Display Table

Assessment of HER2 testing patterns, HER2+ disease, and the utilization of HER2-directed therapy in early breast cancer

Table 1 Demographic and clinical characteristics of the study population stratified based on stage (N=1,458)

Table 2 Status of HER2 testingTable Footnote* before and after the establishment of ASCO/CAP guidelines

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Assessment of HER2 testing patterns, HER2+ disease, and the utilization of HER2-directed therapy in early breast cancer

Figures & data

Table 1 Demographic and clinical characteristics of the study population stratified based on stage (N=1,458)

Table 2 Status of HER2 testingTable Footnote* before and after the establishment of ASCO/CAP guidelines

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date